On January 10, 2026, a forthcoming clinical study was announced to evaluate the effects of two widely used anti-diabetic medications, Henagliflozin Proline Tablets and Metformin XR, on body composition in elderly patients recently diagnosed with Type 2 diabetes mellitus (T2DM). The study, sponsored by a coalition of prestigious institutions including Shanxi Provincial People’s Hospital and Zhongnan Hospital, aims to provide meaningful insights for clinicians and regulatory professionals.
What changed?
The clinical trial, currently not yet recruiting, has been registered under ClinicalTrials.gov, signaling the first steps in exploring the combined impact of Henagliflozin Proline and Metformin XR on geriatric patients with newly diagnosed T2DM. With population aging and diabetes prevalence increasing worldwide, this study addresses a critical gap in understanding how these medications influence body composition in older adults.
What are the specifics of the study?
Purpose of the study
This investigation is centered on examining the physiological effects of Henagliflozin Proline—a sodium-glucose co-transporter 2 (SGLT2) inhibitor—and Metformin XR, an extended-release form of Metformin, on body composition in elderly patients with newly diagnosed T2DM.
Sponsoring institutions
The trial is backed by significant healthcare research stakeholders, including Bin Lu, Shanxi Provincial People’s Hospital, Zhongnan Hospital, the Second Affiliated Hospital of Soochow University, the Second Affiliated Hospital of Shandong First Medical University, and the Fifth Affiliated Hospital of Sun Yat-Sen University. This collaborative effort underscores the significance of the study’s purpose and its high potential impact on clinical care guidelines.
Intervention details
- Henagliflozin Proline Tablets: This oral agent promotes glycemic control by enhancing glucose excretion via the kidneys.
- Metformin XR: A long-standing first-line therapy for T2DM known for improving insulin sensitivity while offering an extended-release formulation to aid patient adherence and tolerance.
The study will evaluate the specific effects of these drugs on parameters like fat mass, lean mass, and other components of body composition.
Why does this matter for stakeholders?
The findings of this study could significantly inform clinical and regulatory bodies on the optimal therapeutic approach for aging T2DM populations. As elderly patients require tailored treatments due to age-related body composition changes, this research may influence treatment guidelines and regulatory decisions. Additionally, it highlights ongoing innovation in combining existing therapies to better address multifactorial conditions like T2DM.
For quality and regulatory professionals, data derived from this trial could provide a stronger basis for recommending or revising drug use parameters in elderly populations. It could also help address safety concerns while optimizing efficacy goals for clinical outcomes.
FAQ
- Who is conducting the study?
The study is sponsored by multiple institutions, including Shanxi Provincial People’s Hospital and Zhongnan Hospital. - What is the focus of the trial?
It aims to evaluate how Henagliflozin Proline and Metformin XR impact body composition in elderly patients with newly diagnosed T2DM. - Has recruitment started?
No, the trial is currently marked as “not yet recruiting.” - Is there a link to the official registration?
Yes, the study is registered on ClinicalTrials.gov. You can access it from the announcement section below.
Conclusion
This upcoming trial represents a significant step in advancing clinical understanding of geriatric diabetes care. Clinicians, researchers, and regulators should monitor updates on this study as it could influence treatment protocols and future research directions.
Disclaimer
This article is for informational purposes only and is not intended to constitute legal advice. Always consult your specific regulatory guidance and legal teams when making clinical or operational decisions.
For full information about the announcement, see the link below.
https://clinicaltrials.gov/study/NCT07323381?term=medical+device